|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Effect of four oral contraceptives on hemostatic parameters. |
| Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H |
| Contraception. 2004;70:97-106. |
| This is the first double-blind, controlled, randomized study comparing the effect of different estrogen components in |
| oral contraceptives (OCs) on hemostasis variables. Four groups of 25 women each were treated for six cycles with |
| monophasic combinations containing 21 tablets with either 30 µg ethinylestradiol (EE) + 2 mg dienogest (DNG) |
| (30EE/DNG), 20 µg EE + 2 mg DNG (20EE/DNG), 10 µg EE + 2 mg estradiol valerate (EV) + 2 mg DNG (EE/EV/DNG) |
| or 20 µg EE + 100 µg levonorgestrel (LNG) (EE/LNG). Blood samples were taken on Days 21-26 of the control cycle |
| and on Days 18-21 of the first, third and sixth treatment cycle. Treatment with all four OCs caused an increase in |
| levels of fibrinogen, prothrombin fragment 1+2, D-dimer, plasminogen, plasmin-antiplasmin complex and an increase |
| in protein C activity, a decrease in antithrombin activity, tissue-plasminogen activator (t-PA) and plasminogen |
| activator inhibitor (PAI), and a slight decrease in the sensitivity to activated protein C, but no significant change in |
| that of the thrombin-antithrombin complex. In users of the DNG-containing OCs, the reduction in total and free protein |
| S, and in t-PA and PAI was dependent on the EE dose, while factor VII activity was elevated, but not significantly |
| different from EE/LNG. The results are in agreement with those of previous studies. The effects of EE/EV/DNG on |
| total and free protein S and on t-PA and PAI were lower than those of 20EE/DNG, suggesting that the impact of 2 mg |
| EV on several hemostasis variables is less than that of 10 µg EE. The results show an antagonistic effect of LNG on |
| the EE-induced rise of factor VII activity and fragment 1_2 and on the EE-dependent reduction of total and free |
| protein S. (PubHealth.info Document ID: CONT1T 532-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Effect of four oral contraceptives on hemostatic |
| parameters.", is(are) Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H. The source of this article is |
| "Contraception. 2004;70:97-106.". This article was published in 2004 in English language(s). (PubHealth.info® |
| Document ID: CONT1T 532-06. All rights reserved with PubHealth.info) PIN: 532 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
